Genelux Corporation (GNLX) vs VAXART, INC. (VXRT)

Genelux Corporation and VAXART, INC. are both Biotechnology companies. Genelux Corporation and VAXART, INC. are of similar size ($92.4M and $88.2M). Genelux Corporation has negative trailing earnings, so its P/E is not meaningful; VAXART, INC. trades at 2.8×. VAXART, INC. has the higher net margin (16.0% vs 0.00%) and the higher return on invested capital (2,515.1% vs 0.00%). Across the 15 metrics below, VAXART, INC. leads on 14 and Genelux Corporation on 1.

Valuation

Metric GNLX VXRT Biotechnology median
P/E n/m 2.83 10.96
P/S 7.80 0.48 9.52
P/B 5.44 1.32 2.23
Price to free cash flow n/m 2.74 25.69
EV/EBITDA n/m 0.67 0.68
EV/Sales 6.89 0.13 9.00
Earnings yield (44.10%) 35.33% (32.09%)
Free cash flow yield (32.72%) 36.53% (22.62%)

Profitability

Metric GNLX VXRT Biotechnology median
Gross margin (3.42%) 100.00% 68.51%
Operating margin 0.00% 16.63% 0.00%
Net margin 0.00% 16.02% 0.00%
Free cash flow margin 0.00% 17.64% 0.00%
Return on equity (177.93%) 62.42% (50.12%)
Return on assets (121.80%) 16.26% (45.12%)
Return on invested capital 0.00% 2,515.10% 0.00%

Growth

Metric GNLX VXRT Biotechnology median
Revenue growth (TTM) — 22.31% 6.78%
EPS growth (last fiscal year) 9.47% 121.21% 29.88%
Revenue growth, 5-year CAGR — 125.76% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GNLX VXRT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.39 1.71 4.74
Net debt to EBITDA 0.44 (2.42) 1.01

Dividend

Metric GNLX VXRT Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric GNLX VXRT Biotechnology median
Market cap 88.23m 92.41m 166.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack